Enanta Pharmaceuticals, Inc., (Nasdaq: ENTA) announced that it has expanded its research and development programs within the company’s core focus areas of virology and liver disease to include new programs to treat hepatitis B virus (HBV) and respiratory syncytial virus (RSV) infections. Enanta also announced that the first subject was dosed in a phase 1 clinical study with EDP-494, its cyclophilin inhibitor for the treatment of hepatitis C virus (HCV).
Enanta has ongoing internal research and development in four disease areas: HCV, HBV, RSV, and non-alcoholic steatohepatitis (NASH). Updates on all four wholly-owned programs will be presented on Wednesday, January 13 at 11:00 a.m. PT at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco.
“Our successful HCV collaboration, our drug discovery expertise and our experience in virology resulted in our first marketed product with AbbVie, paritaprevir, which is part of the VIEKIRA PAK® combination HCV therapy,” commented Jay R. Luly, Ph.D. President and Chief Executive Officer. “We are now in a position to diversify and grow beyond HCV and to expand our research into other areas where we can develop new therapies for patients with limited treatment options.”